<DOC>
	<DOCNO>NCT01262235</DOCNO>
	<brief_summary>This study Phase I/II , open-label , non-randomized , dose-finding trial conduct multiple clinical center . The study design determine safety , tolerability PK TKM-080301 adult patient solid tumor lymphomas refractory standard therapy standard therapy . After determination maximum tolerate dose dose utilized expansion cohort subject refractory neuroendocrine tumor ( NET ) adrenocortical carcinoma ( ACC ) tumor .</brief_summary>
	<brief_title>A Study Determine Safety , Pharmacokinetics Pharmacodynamics Intravenous TKM 080301 Neuroendocrine Tumors ( NET ) Adrenocortical Carcinoma ( ACC ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Adrenocortical Carcinoma</mesh_term>
	<criteria>Patients must histologically cytologically confirm solid tumor refractory standard therapy standard therapy know exist , candidate standard therapy , nonHodgkin 's lymphoma Hodgkin 's disease refractory standard therapy ( i.e. , patient relapse follow least 2 prior therapy ) standard therapy know exist . For Neuroendocrine ( NET ) adrenocortical carcinoma ( ACC ) expansion cohort subject must histologically cytologically confirm , measurable ( per RECIST 1.1 ) NET ACC tumor refractory standard therapy standard therapy know exist , candidate standard therapy . Patient ECOG performance status 0 1 , Patient adequate hematologic , hepatic renal function , Patient seronegative hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) , Patients must life expectancy least 12 week . Unresolved toxicity ( &gt; Grade 1 ) previous chemotherapy , Patients primary tumor central nervous system ( CNS ) , Prophylactic hematologic growth factor administer &lt; /= 2 week prior start therapy , Patient history exist clinically significant cardiovascular disease , Patient history clinically significant asthma COPD require daily medication within last 6 month , Patient seizure disorder control medication , Patient know suspected viral , parasitic , fungal infection , Patient know hypersensitivity previous severe reaction oligonucleotide lipidbased product , include liposomal drug product phospholipidbased product , Patient treat investigational drug , biologics , device within 28 day prior study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Solid tumor</keyword>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
	<keyword>Hodgkin 's Disease</keyword>
	<keyword>Neuroendocrine tumor ( NET )</keyword>
	<keyword>Adrenocortical carcinoma ( ACC )</keyword>
	<keyword>Carcinoid</keyword>
</DOC>